Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods.

Elbasha EH, Chhatwal J.

Med Decis Making. 2015 Jun 19. pii: 0272989X15585121. [Epub ahead of print]

PMID:
26092831
2.

Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach.

Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia MG, Acosta CJ, Elbasha EH.

Value Health. 2015 Jun;18(4):358-67. doi: 10.1016/j.jval.2015.02.004. Epub 2015 Apr 4.

PMID:
26091589
3.

Characterizing Heterogeneity Bias in Cohort-Based Models.

Elbasha EH, Chhatwal J.

Pharmacoeconomics. 2015 Aug;33(8):857-65. doi: 10.1007/s40273-015-0273-z.

PMID:
25851486
4.

Differential characteristics of primary infection and re-infection can cause backward bifurcation in HCV transmission dynamics.

Nazari F, Gumel AB, Elbasha EH.

Math Biosci. 2015 May;263:51-69. doi: 10.1016/j.mbs.2015.02.002. Epub 2015 Feb 14.

PMID:
25686692
5.

Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.

Dan YY, Ferrante SA, Elbasha EH, Hsu TY.

Antivir Ther. 2015;20(2):209-16. doi: 10.3851/IMP2825. Epub 2014 Aug 8.

PMID:
25105844
6.

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH.

Value Health. 2013 Sep-Oct;16(6):973-86. doi: 10.1016/j.jval.2013.07.006.

7.

The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer.

Malik T, Reimer J, Gumel A, Elbasha EH, Mahmud S.

Math Biosci Eng. 2013 Aug;10(4):1173-205. doi: 10.3934/mbe.2013.10.1173.

PMID:
23906207
8.

Model for hepatitis C virus transmissions.

Elbasha EH.

Math Biosci Eng. 2013 Aug;10(4):1045-65. doi: 10.3934/mbe.2013.10.1045.

PMID:
23906202
9.

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.

BMC Infect Dis. 2013 Apr 27;13:190. doi: 10.1186/1471-2334-13-190.

10.

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.

Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.

Appl Health Econ Health Policy. 2013 Feb;11(1):65-78. doi: 10.1007/s40258-012-0007-8.

PMID:
23355388
11.

Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R.

Hepatology. 2013 Jun;57(6):2164-70. doi: 10.1002/hep.26218. Epub 2013 May 6.

12.

Cost-effectiveness of raltegravir in HIV/AIDS.

Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):627-39. doi: 10.1586/erp.11.79. Review.

PMID:
22098278
13.

Prevalence of antibodies associated with herd immunity: a comment.

Elbasha EH.

Med Decis Making. 2011 May-Jun;31(3):511-3; author reply 514-5. doi: 10.1177/0272989X11398667. No abstract available.

PMID:
21610260
14.

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.

Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R.

BMC Med. 2011 May 12;9:54. doi: 10.1186/1741-7015-9-54.

15.

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791.

16.

Impact of vaccinating boys and men against HPV in the United States.

Elbasha EH, Dasbach EJ.

Vaccine. 2010 Oct 4;28(42):6858-67. doi: 10.1016/j.vaccine.2010.08.030. Epub 2010 Aug 14.

PMID:
20713101
17.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

18.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
19.

Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M.

HIV Clin Trials. 2009 Jul-Aug;10(4):233-53. doi: 10.1310/hct1004-233.

PMID:
19723611
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk